PAOG New Pharmaceutical Product Developments Could Generate Rapid Revenue Surge

Rhea-AI Summary

PAO Group, Inc. (OTC PINK: PAOG) announced plans to expand its pharmaceutical development pipeline, focusing on additional products alongside the ongoing RespRx CBD project for Chronic Obstructive Pulmonary Disease (COPD). The company is reviewing opportunities with its CRO partner and other firms to enhance and diversify its offerings. Some identified projects have the potential for rapid revenue generation as early as 2022. More details are expected in the coming weeks.

Positive

• Plans to diversify product pipeline with multiple new pharmaceuticals.
• Identified opportunities with fast-track potential for revenue generation.

Negative

• None.

Sandusky, OH, Nov. 17, 2021 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC PINK: PAOG) today confirmed plans to add multiple new pharmaceutical products to its development pipeline in addition to its ongoing development of its RespRx CBD pharmaceutical for the treatment of Chronic Obstructive Pulmonary Disease (COPD).

The company has been conducting an in-depth review of its current RespRx CBD pharmaceutical development project with its CRO partner, industry consultants and other pharmaceutical firms in an effort to explore various opportunities to accelerate and diversify development.

As the in-depth review continues, PAOG has now identified derivate opportunities from its research to launch additional pharmaceutical product development projects.  The identified opportunities PAOG plans to pursue have fast-track potential and it now appears some of the opportunities have the potential to generate substantial revenue rapidly as early as next year in 2022.

PAOG anticipates releasing more information on specific opportunities sin the coming weeks.

Learn more about PAOG at www.paogroupinc.com.

Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

CONTACT INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
info@pao.group

FAQ

What new products is PAOG planning to develop?

PAOG is planning to add multiple new pharmaceutical products to its development pipeline, focusing on opportunities alongside the RespRx CBD pharmaceutical.

When can we expect to see revenue from PAOG's new product developments?

PAOG anticipates that some of the new opportunities could generate substantial revenue as early as 2022.

What is the current status of PAOG's RespRx project?

PAOG is continuing the development of its RespRx CBD pharmaceutical for Chronic Obstructive Pulmonary Disease (COPD) while exploring additional product opportunities.

Who is PAOG's CRO partner involved in product development?

The press release does not specify the name of PAOG's CRO partner involved in the development of its pharmaceutical projects.

What should investors know about PAOG's future plans?

Investors should note that PAOG is in the process of reviewing its product development strategy, which includes opportunities that could lead to substantial revenue.